AnnexonANNX
ANNX
About: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Employees: 103
0
Funds holding %
of 7,432 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
24% more capital invested
Capital invested by funds: $192M [Q1] → $238M (+$45.7M) [Q2]
0.36% less ownership
Funds ownership: 90.91% [Q1] → 90.54% (-0.36%) [Q2]
14% less funds holding
Funds holding: 146 [Q1] → 126 (-20) [Q2]
43% less call options, than puts
Call options by funds: $50K | Put options by funds: $88K
47% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 36
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
551%
upside
Avg. target
$14
551%
upside
High target
$14
551%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ananda Ghosh | 551%upside $14 | Buy Reiterated | 15 Aug 2025 |
Financial journalist opinion
Based on 3 articles about ANNX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 week ago
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million in Cash Supports Operations into the Fourth Quarter of 2026 Through Vonaprument Topline Phase 3 Data in GA BRISBANE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress, announced key anticipated milestones and reported second quarter 2025 financial results.
Neutral
GlobeNewsWire
2 weeks ago
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
Neutral
GlobeNewsWire
1 month ago
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for July 22nd
BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.
Negative
Seeking Alpha
1 month ago
Annexon: Lead GBS Therapy Stokes Near-Term Potential
Annexon is a speculative Buy due to its late-stage Tanruprubart program targeting the high unmet need in Guillain-Barré Syndrome. Tanruprubart could become the standard of care for GBS if approved, given the lack of FDA-approved therapies and limited competition. The company faces near-term risks: delayed regulatory filings, high cash burn, and a likely need for additional funding within a year.
Neutral
GlobeNewsWire
2 months ago
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors
Neutral
GlobeNewsWire
2 months ago
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST.
Neutral
GlobeNewsWire
3 months ago
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations
Neutral
GlobeNewsWire
3 months ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 14, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™